Fracture risks in patients with arginine vasopressin deficiency: a nationwide matched cohort study
Main finding · Hip fractures, womenResult — go to the resultHazard ratio 1.83 95% CI 1.06–3.17Authors' conclusion
Compared with controls, only female patients with AVP-D demonstrated a significantly increased risk of HFs.
Study context
- Population
- Patients aged ≥ 50 years with arginine vasopressin deficiency, Korea National Health Insurance Service database (2003–2020)3,497 arginine vasopressin deficiency (AVP-D) (2,111 men, 1,386 women)
- Exposure
- AVP-D vs matched controls
- AVP-Dn = 3,497
- Outcome
- Risk of major osteoporotic fractures, vertebral fractures, non-vertebral fractures and hip fractures
Methodological detailsnationwide, 1:1 matched on age, sex, index year and key comorbidities, Cox proportional hazards models
- Nationwide
- 1:1 matched on age, sex, index year and key comorbidities
- Cox proportional hazards models
Main finding
Hip fractures, women
Hazard ratio
1.83
95% CI 1.06–3.17
AVP-Dvs Controls
HR 1.83 (95% CI 1.06–3.17)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Risk factors for fracture in AVP-D
- Age, female, previous history of fracture and steroid use contributed to high fracture risk
Original publication
Fracture risks in patients with arginine vasopressin deficiency: a nationwide matched cohort study. Osteoporos Int. Published 28 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →